We hypothesized that if increased expression of IFN-β-inducible genes in untreated MS patients interfered with CD4+ T-cell reactivity to MBP ex vivo, IFN-β treatment might also do so. The gene discussed is IFNB1; the disease is myeloid sarcoma.